Agios Pharmaceuticals (NASDAQ:AGIO) Stock: Insider Sarah Gheuens Sells 7,866 Shares

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) insider Sarah Gheuens sold 7,866 shares of the company’s stock in a transaction that occurred on Monday, October 26th. The stock was sold at an average price of $37.69, for a total transaction of $296,469.54. Following the sale, the insider directly owned 54,645 shares in the company, valued at approximately $2,059,570.05. The trade was a 12.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sarah Gheuens also recently made the following trade(s):

• On Thursday, October 22nd, Sarah Gheuens sold 500 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $37.52, for a total transaction of $18,760.00.
• On Wednesday, October 21st, Sarah Gheuens sold 1,489 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $37.53, for a total transaction of $55,882.17.
• On Tuesday, August 4th, Sarah Gheuens sold 30,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $30.48, for a total transaction of $914,400.00.

Agios Pharmaceuticals Price Performance

Shares of AGIO traded up $0.09 during midday trading on Wednesday, reaching $38.12. The stock had a trading volume of 912,920 shares, compared to its average volume of 1,055,831. Agios Pharmaceuticals, Inc. has a 1-year low of $22.24 and a 1-year high of $46.00. The company’s fifty day simple moving average is $33.57 and its two-hundred day simple moving average is $31.60. The company has a market cap of $2.28 billion, a price-to-earnings ratio of -5.44 and a beta of 0.63.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($1.65) by ($0.04). The business had revenue of $44.75 million during the quarter, compared to analysts’ expectations of $26.39 million. Agios Pharmaceuticals had a negative net margin of 418.24% and a negative return on equity of 35.67%. On average, sell-side analysts forecast that Agios Pharmaceuticals, Inc. will post -5.83 earnings per share for the current year.

Institutional Trading of Agios Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new stake in Agios Pharmaceuticals during the 2nd quarter worth approximately $239,582,000. Assenagon Asset Management S.A. increased its holdings in shares of Agios Pharmaceuticals by 1,714.6% in the third quarter. Assenagon Asset Management S.A. now owns 1,886,412 shares of the biopharmaceutical company’s stock valued at $62,723,000 after purchasing an additional 1,782,457 shares during the period. ADAR1 Capital Management LLC acquired a new position in shares of Agios Pharmaceuticals in the second quarter valued at approximately $47,800,000. Dimensional Fund Advisors LP raised its stake in shares of Agios Pharmaceuticals by 14.7% during the first quarter. Dimensional Fund Advisors LP now owns 1,151,614 shares of the biopharmaceutical company’s stock worth $38,940,000 after purchasing an additional 147,273 shares during the last quarter. Finally, Parkman Healthcare Partners LLC purchased a new stake in shares of Agios Pharmaceuticals during the second quarter worth approximately $24,828,000.

Analysts Set New Price Targets

Several research analysts have commented on the company. Citigroup lifted their price target on Agios Pharmaceuticals from $46.00 to $52.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Bank of America raised their target price on shares of Agios Pharmaceuticals from $46.00 to $50.00 and gave the stock a “buy” rating in a research report on Monday, September 21st. JPMorgan Chase & Co. raised their target price on shares of Agios Pharmaceuticals from $31.00 to $34.00 and gave the stock a “neutral” rating in a research report on Friday, August 7th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Agios Pharmaceuticals in a report on Monday, September 21st. Finally, HC Wainwright upped their price target on shares of Agios Pharmaceuticals from $52.00 to $55.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $41.50.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering and developing medicines for rare diseases involving cellular metabolism. The company’s research is centered on metabolic pathways that influence red blood cell production and function, with the goal of addressing conditions that have limited treatment options.

Agios’ principal commercial product is Pyrukynd (mitapivat), an oral activator of pyruvate kinase. Pyrukynd is approved in the United States and other markets for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency, a rare inherited blood disorder.